APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Nina Tunariu discussing monitoring with whole body MRI. Dr. Tunariu started ...

For patients with metachronous low burden mCSPC on conventional imaging being recommended for systemic therapy, 51% responded ...

APCCC Diagnostics annual meeting featured a session on what we should know for PSMA radioligand therapy and a presentation by ...

(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Himisha Beltran discussing when we should assess ...

APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr.

APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Alexander Wyatt discussing when we should assess biology with ctDNA. Cell ...

Dr. Tombal notes that from the ENZAMET trial, 1 we have made significant progress in survival among men with newly diagnosed mHSPC, but there are still 30-40% of men that die at 5 years, and many will ...

(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of biochemically ...

(UroToday.com) Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of metastatic prostate ...

(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...

APCCC Diagnostics annual meeting featured a session on what we should know for PSMA radioligand therapy and a presentation by Dr. Joe O'Sullivan discussing what we should have reported in an MRI and ...

Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively impacts survivors. Few risk factors are known beyond the radiation dose and volume of bladder ...